Certolizumab pegol
- Generic Name
- Certolizumab pegol
- Brand Names
- Cimzia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 428863-50-7
- Unique Ingredient Identifier
- UMD07X179E
- Background
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cyt...
- Indication
Certolizumab pegol has been approved for several different conditions listed below:
...
- Associated Conditions
- Moderate to Severe Plaque Psoriasis, Moderately to Severely Active Rheumatoid Arthritis, Non-radiographic Axial Spondyloarthritis, Psoriatic Arthritis, Severe Crohn's Disease, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Crohn’s Disease, Moderate Psoriatic Arthritis, Moderate Rheumatoid arthritis, Severe Psoriatic Arthritis, Severe Rheumatoid arthritis
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath